// App-Quantinova.ai

PB2113 : FRONTMIND: A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TAFASITAMAB + LENALIDOMIDE + R-CHOP VS R-CHOP ALONE FOR NEWLY DIAGNOSED HIGH-INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA

Researchers

Presenter

  • Umberto Vitolo

Principal Investigators

  • Grzegorz S. Nowakowski

  • John M. Burke

  • Christopher P. Fox

  • Marek Trneny

  • Annalisa Chiappella

  • Maeve Waldron-Lynch

  • Nira Hadar

  • Alok Pachori

  • Georg Lenz

Medical Centers

  • Department of Medicine A / Hematology and Oncology, University of Muenster, Muenster, Germany

  • Department of Clinical Hematology,Nottingham University Hospitals NHS,Nottingham,Соединённое Королевство

  • Stem Cell Transplant,Fondazione IRCCS, Istituto Nazionale dei Tumori,Milan,Italia

  • Candiolo Cancer Institue - FPO, IRCCS, Turin, Italy

  • Department of Medicine A – Haematology and Oncology,University Hospital Münster,Münster,Duitsland

  • 1st Department of Medicine, First Medical Faculty,Charles University and General University Hospital,Prague,Czech

  • Department of Hematology,US Oncology Research and Rocky Mountain Cancer Centers,Aurora,États-unis

  • Candiolo Cancer Institue - FPO, IRCCS, Turin, Italy

  • Department of Medicine A, Hematology and Oncology,University Hospital Muenster,Münster,Deutschland

  • Department of Clinical Hematology,Nottingham University Hospitals NHS,Nottingham,Storbritannien

  • 1st Department of Medicine, First Medical Faculty,Charles University and General University Hospital,Prague,Czech

  • Department of Hematology,US Oncology Research and Rocky Mountain Cancer Centers,Aurora,États-unis

  • 1st Department of Medicine, First Medical Faculty,Charles University and General University Hospital,Prague,Czech

  • Division of Hematology, Mayo Clinic,Rochester, MN,États-unis

  • Department of Hematology,US Oncology Research and Rocky Mountain Cancer Centers,Aurora,États-unis

  • Stem Cell Transplant,Fondazione IRCCS, Istituto Nazionale dei Tumori,Milan,Italia

  • Candiolo Cancer Institue - FPO, IRCCS, Turin, Italy

  • Stem Cell Transplant,Fondazione IRCCS, Istituto Nazionale dei Tumori,Milan,Italia

  • Stem Cell Transplant,Fondazione IRCCS, Istituto Nazionale dei Tumori,Milan,Italia

  • Department of Hematology,US Oncology Research and Rocky Mountain Cancer Centers,Aurora,États-unis

  • Department of Clinical Hematology,Nottingham University Hospitals NHS,Nottingham,Storbritannien

  • Division of Epidemiology, Mayo Clinic, Rochester, United States

  • MorphoSys US, Inc.,Boston,USA

  • 1st Department of Medicine, First Medical Faculty,Charles University and General University Hospital,Prague,Czech

  • MorphoSys US, Inc.,Boston,Estados Unidos

  • Department of Hematology,US Oncology Research and Rocky Mountain Cancer Centers,Aurora,États-unis

  • Department of Medicine A – Haematology and Oncology,University Hospital Münster,Münster,Duitsland

  • 1st Department of Medicine, First Medical Faculty,Charles University and General University Hospital,Prague,Czech

  • Division of Hematopathology, Mayo Clinic, Rochester, MN

  • Candiolo Cancer Institue - FPO, IRCCS, Turin, Italy

  • Department of Medicine A – Haematology and Oncology,University Hospital Münster,Münster,Duitsland

  • Division of Hematology,Mayo Clinic,Rochester,Verenigde Staten

  • Department of Hematology,US Oncology Research and Rocky Mountain Cancer Centers,Aurora,États-unis

  • Division of Hematology,Mayo Clinic,Rochester,Verenigde Staten

  • Division of Hematology, Mayo Clinic,Rochester, MN,États-unis

  • MorphoSys US,Boston,Vereinigte Staaten

  • MorphoSys US,Boston,United States

  • MorphoSys US,Boston,Vereinigte Staaten

  • Stem Cell Transplant,Fondazione IRCCS, Istituto Nazionale dei Tumori,Milan,Italia

  • 1st Department of Medicine, First Medical Faculty,Charles University and General University Hospital,Prague,Czech

  • Candiolo Cancer Center, FPO-IRCCS, Candiolo (Torino), Italy

  • Stem Cell Transplant,Fondazione IRCCS, Istituto Nazionale dei Tumori,Milan,Italia

  • Department of Clinical Hematology,Nottingham University Hospitals NHS,Nottingham,Storbritannien

  • Candiolo Cancer Institue - FPO, IRCCS, Turin, Italy

  • 1st Department of Medicine, First Medical Faculty,Charles University and General University Hospital,Prague,Czech

  • 1st Department of Medicine, First Medical Faculty,Charles University and General University Hospital,Prague,Czech

  • Stem Cell Transplant,Fondazione IRCCS, Istituto Nazionale dei Tumori,Milan,Italia

  • Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, United Kingdom

  • Candiolo Cancer Institute, FPO-IRCCS,Candiolo (Torino),Италия

  • Division of Hematology, Mayo Clinic,Rochester, MN,États-unis

  • Department of Hematology,US Oncology Research and Rocky Mountain Cancer Centers,Aurora,États-unis

  • Department of Clinical Hematology,Nottingham University Hospitals NHS,Nottingham,Storbritannien

  • Department of Clinical Hematology,Nottingham University Hospitals NHS,Nottingham,Storbritannien

  • 1st Department of Medicine, First Medical Faculty,Charles University and General University Hospital,Prague,Czech

  • MorphoSys US Inc.,Boston,Stati Uniti

  • Department of Medicine A – Haematology and Oncology,University Hospital Münster,Münster,Duitsland

  • MorphoSys US, Inc.,Boston,États-unis

  • Division of Hematology &amp

  • Department of Medicine A / Hematology and Oncology, University of Muenster, Muenster, Germany

  • Department of Clinical Hematology,Nottingham University Hospitals NHS,Nottingham,Storbritannien

  • Department of Medicine A – Haematology and Oncology,University Hospital Münster,Münster,Duitsland

Locations

  • Italy

  • United States

  • United Kingdom

  • Czech Republic

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

Biomarkers

  • Cytokeratin 20

Drug/Treatment

  • Lenalidomide

  • Tafasitamab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT03274492

  • NCT02399085

  • NCT04134936

  • NCT04824092

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved